Literature DB >> 33564925

Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids.

Jacob X M Truong1,2,3, Xander Spotbeen1,4, Jake White1,2, Johannes V Swinnen4, Lisa M Butler1,2,3, Marten F Snel1,2, Paul J Trim5,6.   

Abstract

Matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) is a common molecular imaging modality used to characterise the abundance and spatial distribution of lipids in situ. There are several technical challenges predominantly involving sample pre-treatment and preparation which have complicated the analysis of clinical tissues by MALDI-MSI. Firstly, the common embedding of samples in optimal cutting temperature (O.C.T.), which contains high concentrations of polyethylene glycol (PEG) polymers, causes analyte signal suppression during mass spectrometry (MS) by competing for available ions during ionisation. This suppressive effect has constrained the application of MALDI-MSI for the molecular mapping of clinical tissues. Secondly, the complexity of the mass spectra is obtained by the formation of multiple adduct ions. The process of analyte ion formation during MALDI can generate multiple m/z peaks from a single lipid species due to the presence of alkali salts in tissues, resulting in the suppression of protonated adduct formation and the generation of multiple near isobaric ions which produce overlapping spatial distributions. Presented is a method to simultaneously remove O.C.T. and endogenous salts. This approach was applied to lipid imaging in order to prevent analyte suppression, simplify data interpretation, and improve sensitivity by promoting lipid protonation and reducing the formation of alkali adducts.

Entities:  

Keywords:  Ammonium formate; Lipids; MALDI imaging; O.C.T.; Washing

Mesh:

Substances:

Year:  2021        PMID: 33564925     DOI: 10.1007/s00216-020-03128-z

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  53 in total

1.  Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.

Authors:  Elizabeth C Randall; Giorgia Zadra; Paolo Chetta; Begona G C Lopez; Sudeepa Syamala; Sankha S Basu; Jeffrey N Agar; Massimo Loda; Clare M Tempany; Fiona M Fennessy; Nathalie Y R Agar
Journal:  Mol Cancer Res       Date:  2019-02-11       Impact factor: 5.852

Review 2.  Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development.

Authors:  Sandra Schulz; Michael Becker; M Reid Groseclose; Simone Schadt; Carsten Hopf
Journal:  Curr Opin Biotechnol       Date:  2018-08-25       Impact factor: 9.740

3.  MALDI imaging mass spectrometry to investigate endogenous peptides in an animal model of Usher's disease.

Authors:  Bijon Chatterji; Clarissa Dickhut; Svenja Mielke; Jonas Krüger; Ingo Just; Silke Glage; Martin Meier; Dirk Wedekind; Andreas Pich
Journal:  Proteomics       Date:  2014-06-20       Impact factor: 3.984

4.  In Situ Imaging of Tryptic Peptides by MALDI Imaging Mass Spectrometry Using Fresh-Frozen or Formalin-Fixed, Paraffin-Embedded Tissue.

Authors:  Peggi M Angel; Kim Norris-Caneda; Richard R Drake
Journal:  Curr Protoc Protein Sci       Date:  2018-08-16

5.  MALDI imaging MS of phospholipids in the mouse lung.

Authors:  Karin A Zemski Berry; Bilan Li; Susan D Reynolds; Robert M Barkley; Miguel A Gijón; Joseph A Hankin; Peter M Henson; Robert C Murphy
Journal:  J Lipid Res       Date:  2011-04-20       Impact factor: 5.922

Review 6.  Lipid imaging by mass spectrometry - a review.

Authors:  David Gode; Dietrich A Volmer
Journal:  Analyst       Date:  2013-03-07       Impact factor: 4.616

7.  Improved matrix coating for positive- and negative-ion-mode MALDI-TOF imaging of lipids in blood vessel tissues.

Authors:  Christina Meisenbichler; Christian Doppler; David Bernhard; Thomas Müller
Journal:  Anal Bioanal Chem       Date:  2019-04-30       Impact factor: 4.142

8.  The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer.

Authors:  Takayuki Goto; Naoki Terada; Takahiro Inoue; Kenji Nakayama; Yoshiyuki Okada; Takeshi Yoshikawa; Yu Miyazaki; Masayuki Uegaki; Shinji Sumiyoshi; Takashi Kobayashi; Tomomi Kamba; Koji Yoshimura; Osamu Ogawa
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

9.  Mass Spectrometry Imaging Demonstrates the Regional Brain Distribution Patterns of Three First-Line Antiretroviral Drugs.

Authors:  Sphamandla Ntshangase; Sipho Mdanda; Sanil D Singh; Tricia Naicker; Hendrik G Kruger; Sooraj Baijnath; Thavendran Govender
Journal:  ACS Omega       Date:  2019-12-05

10.  Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry.

Authors:  Shadrack M Mutuku; Paul J Trim; Bala K Prabhala; Swati Irani; Kayla L Bremert; Jessica M Logan; Douglas A Brooks; Jürgen Stahl; Margaret M Centenera; Marten F Snel; Lisa M Butler
Journal:  Sci Rep       Date:  2019-10-18       Impact factor: 4.379

View more
  1 in total

1.  Sample preparation optimization of insects and zebrafish for whole-body mass spectrometry imaging.

Authors:  Lianlian Ma; Qingrong Xie; Mingyi Du; Yudi Huang; Yingying Chen; Dong Chen; Yizhu Xu; Hanhong Xu; Xinzhou Wu; Zhibin Yin
Journal:  Anal Bioanal Chem       Date:  2022-05-04       Impact factor: 4.142

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.